抗寨卡病毒感染治疗药物的研究进展。
Advancement in the Development of Therapeutics Against Zika Virus Infection.
机构信息
Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China.
Key Laboratory of Medical Molecular Virology of Ministry of Education (MOE), National Health Commission (NHC) and Chinese Academy of Medical Sciences (CAMS), School of Basic Medical Sciences and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
出版信息
Front Cell Infect Microbiol. 2022 Jul 8;12:946957. doi: 10.3389/fcimb.2022.946957. eCollection 2022.
Abstract
Zika virus (ZIKV), a re-emerging arbovirus, causes teratogenic effects on the fetus and normal nerve functions, resulting in harmful autoimmune responses, which call for the development of therapeutics against ZIKV infection. In this review, we introduce the pathogenesis of ZIKV infection and summarize the advancement in the development of therapeutics against ZIKV infection. It provides guidance for the development of effective therapeutics against ZIKV infection.
摘要
寨卡病毒（ZIKV）是一种重新出现的虫媒病毒，会对胎儿和正常神经功能造成致畸作用，导致有害的自身免疫反应，因此需要开发针对 ZIKV 感染的治疗方法。在这篇综述中，我们介绍了 ZIKV 感染的发病机制，并总结了针对 ZIKV 感染的治疗方法的进展。这为开发针对 ZIKV 感染的有效治疗方法提供了指导。
相似文献
1
Advancement in the Development of Therapeutics Against Zika Virus Infection.
Front Cell Infect Microbiol. 2022 Jul 8;12:946957. doi: 10.3389/fcimb.2022.946957. eCollection 2022.
2
NS2B-NS3 protease inhibitors as promising compounds in the development of antivirals against Zika virus: A systematic review.
J Med Virol. 2022 Feb;94(2):442-453. doi: 10.1002/jmv.27386. Epub 2021 Oct 20.
3
Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists.
Antiviral Res. 2017 Jul;143:218-229. doi: 10.1016/j.antiviral.2017.04.015. Epub 2017 Apr 29.
4
Discovery of Bispecific Lead Compounds from against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations.
Molecules. 2022 Apr 15;27(8):2562. doi: 10.3390/molecules27082562.
5
Zika Virus NS2A-Mediated Virion Assembly.
mBio. 2019 Oct 29;10(5):e02375-19. doi: 10.1128/mBio.02375-19.
6
The Structure of the Zika Virus Protease, NS2B/NS3.
Adv Exp Med Biol. 2018;1062:131-145. doi: 10.1007/978-981-10-8727-1_10.
7
Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through approaches.
J Biomol Struct Dyn. 2021 Jan;39(1):272-284. doi: 10.1080/07391102.2019.1709546. Epub 2020 Jan 10.
8
The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach.
Eur J Pharm Sci. 2022 Aug 1;175:106220. doi: 10.1016/j.ejps.2022.106220. Epub 2022 May 23.
9
Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease.
J Biomol Struct Dyn. 2020 Nov;38(18):5526-5536. doi: 10.1080/07391102.2019.1704882. Epub 2019 Dec 27.
10
Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease.
Biochem Biophys Res Commun. 2017 Oct 28;492(4):668-673. doi: 10.1016/j.bbrc.2017.03.108. Epub 2017 Mar 22.
引用本文的文献
1
Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA-14-2.
Int J Mol Sci. 2024 Dec 29;26(1):195. doi: 10.3390/ijms26010195.
2
Envelope Protein-Targeting Zika Virus Entry Inhibitors.
Int J Mol Sci. 2024 Aug 30;25(17):9424. doi: 10.3390/ijms25179424.
3
A high-throughput cell-based screening method for Zika virus protease inhibitor discovery.
SLAS Discov. 2024 Jul;29(5):100164. doi: 10.1016/j.slasd.2024.100164. Epub 2024 May 24.
4
Ago-Based Zika Virus Detection.
Viruses. 2024 Mar 30;16(4):539. doi: 10.3390/v16040539.
5
Zika virus remodelled ER membranes contain proviral factors involved in redox and methylation pathways.
Nat Commun. 2023 Dec 5;14(1):8045. doi: 10.1038/s41467-023-43665-6.
6
Mechanisms of Zika astrocyte infection and neuronal toxicity.
NeuroImmune Pharm Ther. 2023 Mar 25;2(1):5-18. doi: 10.1515/nipt-2022-0014. Epub 2022 Oct 21.
本文引用的文献
1
Discovery of Bispecific Lead Compounds from against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations.
Molecules. 2022 Apr 15;27(8):2562. doi: 10.3390/molecules27082562.
2
Zika Virus Overview: Transmission, Origin, Pathogenesis, Animal Model and Diagnosis.
Zoonoses. 2021;1(1). doi: 10.15212/zoonoses-2021-0017. Epub 2021 Dec 7.
3
Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors.
Bioorg Chem. 2021 Apr;109:104719. doi: 10.1016/j.bioorg.2021.104719. Epub 2021 Feb 11.
4
The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion.
Viruses. 2020 Dec 21;12(12):1475. doi: 10.3390/v12121475.
5
AHR is a Zika virus host factor and a candidate target for antiviral therapy.
Nat Neurosci. 2020 Aug;23(8):939-951. doi: 10.1038/s41593-020-0664-0. Epub 2020 Jul 20.
6
Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery.
Sci Rep. 2020 Jun 2;10(1):8929. doi: 10.1038/s41598-020-65489-w.
7
Inhibitors of the Zika virus protease NS2B-NS3.
Bioorg Med Chem Lett. 2020 Mar 1;30(5):126965. doi: 10.1016/j.bmcl.2020.126965. Epub 2020 Jan 11.
8
Zika virus enhances monocyte adhesion and transmigration favoring viral dissemination to neural cells.
Nat Commun. 2019 Sep 27;10(1):4430. doi: 10.1038/s41467-019-12408-x.
9
Discovery and Computational Analyses of Novel Small Molecule Zika Virus Inhibitors.
Molecules. 2019 Apr 13;24(8):1465. doi: 10.3390/molecules24081465.
10
Mechanism of Action of Methotrexate Against Zika Virus.
Viruses. 2019 Apr 10;11(4):338. doi: 10.3390/v11040338.
Zotero 插件